Compare SAR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAR | MYGN |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.7M | 444.2M |
| IPO Year | N/A | 1996 |
| Metric | SAR | MYGN |
|---|---|---|
| Price | $22.62 | $4.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $23.75 | $7.64 |
| AVG Volume (30 Days) | 110.3K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 14.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | $0.39 | $5.45 |
| P/E Ratio | $9.44 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $20.78 | $3.76 |
| 52 Week High | $25.64 | $8.59 |
| Indicator | SAR | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 48.86 |
| Support Level | $22.56 | $4.25 |
| Resistance Level | $22.82 | $5.52 |
| Average True Range (ATR) | 0.49 | 0.30 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 48.24 | 45.24 |
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.